Drugs / DB-1324
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07263594 | Jan 2026 → Dec 2028 expected | digestive system cancer | DualityBio Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-12-03 | DualityBio Inc. | Regulatory DualityBio's Innovative ADC DB-1324 Receives FDA IND Clearance, Set to Initiate Clinical Trial in the United States dualitybiologics.com ↗ |
| 2025-10-14 | DualityBio Inc. | Regulatory DualityBio DB-1324 HREC approval obtained and received TGA acknowledgment of the eCTN dualitybiologics.com ↗
DualityBio (HKEX: 9606.HK) today announced that its DB-1324 project has received clinical trial approval for solid tumors from the Human Research Ethics Committee (HREC) and also received the Therapeutic Goods Administration (TGA) in Australia. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-03 | DualityBio Inc. | DualityBio's Innovative ADC DB-1324 Receives FDA IND Clearance, Set to Initiate Clinical Trial in the United States dualitybiologics.com ↗ |
| 2025-10-14 | DualityBio Inc. | DualityBio DB-1324 HREC approval obtained and received TGA acknowledgment of the eCTN dualitybiologics.com ↗ |
| 2024-12-03 | DualityBio Inc. | Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324) dualitybiologics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DB-1324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07263594 ↗ |
| Route | Intravenous | “Administered I.V.” NCT07263594 ↗ |